We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gear Up for Haemonetics (HAE) Q4 Earnings: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts expect Haemonetics (HAE - Free Report) to post quarterly earnings of $1.22 per share in its upcoming report, which indicates a year-over-year increase of 35.6%. Revenues are expected to be $327.34 million, down 4.7% from the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 3.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Haemonetics metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Net revenues- Plasma' will reach $127.03 million. The estimate indicates a change of -8.4% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net revenues- Hospital' will likely reach $147.41 million. The estimate points to a change of +14.1% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Net revenues- Blood Center' of $53.14 million. The estimate suggests a change of -24.3% year over year.
Over the past month, Haemonetics shares have recorded returns of +13.5% versus the Zacks S&P 500 composite's +10.6% change. Based on its Zacks Rank #4 (Sell), HAE will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gear Up for Haemonetics (HAE) Q4 Earnings: Wall Street Estimates for Key Metrics
Wall Street analysts expect Haemonetics (HAE - Free Report) to post quarterly earnings of $1.22 per share in its upcoming report, which indicates a year-over-year increase of 35.6%. Revenues are expected to be $327.34 million, down 4.7% from the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 3.3% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
With that in mind, let's delve into the average projections of some Haemonetics metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts predict that the 'Net revenues- Plasma' will reach $127.03 million. The estimate indicates a change of -8.4% from the prior-year quarter.
The combined assessment of analysts suggests that 'Net revenues- Hospital' will likely reach $147.41 million. The estimate points to a change of +14.1% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Net revenues- Blood Center' of $53.14 million. The estimate suggests a change of -24.3% year over year.
View all Key Company Metrics for Haemonetics here>>>
Over the past month, Haemonetics shares have recorded returns of +13.5% versus the Zacks S&P 500 composite's +10.6% change. Based on its Zacks Rank #4 (Sell), HAE will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>